Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Abroad (travel likely)RecruitingPHASE1

Conditions

Hepatic Impairment · Moderate Hepatic Impairment

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Exelixis Clinical Site #1, Orlando, Florida, United States
Exelixis Clinical Site #2, San Antonio, Texas, United States

Study leads

Medical Director
Study Director
Exelixis

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function

Healthy Participants · Participants With Mild Hepatic Impairment · Participants With Moderate Hepatic Impairment

Abroad (travel likely)RecruitingPHASE1

Suzhou, China

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Hepatic Impairment

Abroad (travel likely)RecruitingPHASE1

Chandler, United States · Rialto, United States

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

Healthy · Hepatic Impairment

Abroad (travel likely)RecruitingPHASE1

Miami, United States · Orlando, United States

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

Hepatic Impairment

Abroad (travel likely)RecruitingPHASE1

Lake Forest, United States · Orlando, United States